These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9240694)

  • 1. Development of novel influenza virus vaccines and vectors.
    Palese P; Zavala F; Muster T; Nussenzweig RS; García-Sastre A
    J Infect Dis; 1997 Aug; 176 Suppl 1():S45-9. PubMed ID: 9240694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant influenza virus expressing HIV-1 p24 capsid protein induces mucosal HIV-specific CD8 T-cell responses.
    Tan HX; Gilbertson BP; Jegaskanda S; Alcantara S; Amarasena T; Stambas J; McAuley JL; Kent SJ; De Rose R
    Vaccine; 2016 Feb; 34(9):1172-9. PubMed ID: 26826545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity.
    Rodrigues M; Li S; Murata K; Rodriguez D; Rodriguez JR; Bacik I; Bennink JR; Yewdell JW; Garcia-Sastre A; Nussenzweig RS
    J Immunol; 1994 Nov; 153(10):4636-48. PubMed ID: 7525709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses.
    Mueller SN; Langley WA; Carnero E; García-Sastre A; Ahmed R
    J Virol; 2010 Feb; 84(4):1847-55. PubMed ID: 19939929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.
    Di Mario G; Sciaraffia E; Facchini M; Gubinelli F; Soprana E; Panigada M; Bernasconi V; Garulli B; Siccardi A; Donatelli I; Castrucci MR
    Pathog Glob Health; 2017 Mar; 111(2):76-82. PubMed ID: 28079473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral immunization with recombinant Lactococcus lactis expressing the hemagglutinin of the avian influenza virus induces mucosal and systemic immune responses.
    Wang Z; Gao J; Yu Q; Yang Q
    Future Microbiol; 2012 Aug; 7(8):1003-10. PubMed ID: 22913358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
    Kingstad-Bakke B; Kamlangdee A; Osorio JE
    Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.
    Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W
    Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii.
    González-Aseguinolaza G; Nakaya Y; Molano A; Dy E; Esteban M; Rodríguez D; Rodríguez JR; Palese P; García-Sastre A; Nussenzweig RS
    J Virol; 2003 Nov; 77(21):11859-66. PubMed ID: 14557672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
    He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
    Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains.
    Jang YH; Lee EY; Byun YH; Jung EJ; Lee YJ; Lee YH; Lee KH; Lee J; Seong BL
    Vaccine; 2014 Jan; 32(5):535-43. PubMed ID: 24342248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus.
    Garulli B; Kawaoka Y; Castrucci MR
    J Virol; 2004 Jan; 78(2):1020-5. PubMed ID: 14694134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose.
    Dhanwani R; Zhou Y; Huang Q; Verma V; Dileepan M; Ly H; Liang Y
    J Virol; 2015 Dec; 90(5):2551-60. PubMed ID: 26676795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
    Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
    J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.